Thomas J Ettrich
Overview
Explore the profile of Thomas J Ettrich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
556
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beutel A, Ekizce M, Ettrich T, Seufferlein T, Lindenmayer J, Gout J, et al.
United European Gastroenterol J
. 2024 Nov;
13(1):21-33.
PMID: 39540683
Pancreatic ductal adenocarcinoma (PDAC) ranks among the leading causes of cancer-related deaths worldwide. Despite advances in precision oncology in other malignancies, treatment of PDAC still largely relies on conventional chemotherapy....
2.
Tintelnot J, Paschold L, Goekkurt E, Schultheiss C, Matschl U, Santos Cruz M, et al.
Cancer Immunol Res
. 2024 Nov;
13(2):200-209.
PMID: 39527097
Anti-PD-1, trastuzumab, and chemotherapy are used in the treatment of patients with advanced HER2-positive esophagogastric adenocarcinoma, but long-term survival remains limited. In this study, we report extended follow-up data from...
3.
Perkhofer L, Seufferlein T, Melzer A, Ettrich T
J Clin Oncol
. 2024 Oct;
43(3):357-359.
PMID: 39467218
No abstract available.
4.
Seufferlein T, Mayerle J, Boeck S, Brunner T, Ettrich T, Grenacher L, et al.
Z Gastroenterol
. 2024 Oct;
62(10):1724-1785.
PMID: 39389105
No abstract available.
5.
Seufferlein T, Mayerle J, Boeck S, Brunner T, Ettrich T, Grenacher L, et al.
Z Gastroenterol
. 2024 Oct;
62(10):e874-e995.
PMID: 39389103
No abstract available.
6.
Scheck M, Goetze T, Ettrich T, Schmalenberg H, Clemens M, Mahlberg R, et al.
Oncol Res Treat
. 2024 Sep;
47(11):549-560.
PMID: 39250905
Introduction: In squamous cell carcinoma of the esophagus (ESCC), therapeutical options in 2nd-line treatment are scarce with immune checkpoint inhibition being the only approved one. Ramucirumab/paclitaxel is an approved 2nd-line...
7.
Dorman K, Boeck S, Caca K, Reichert M, Ettrich T, Oettle H, et al.
Lancet Gastroenterol Hepatol
. 2024 Aug;
9(10):935-943.
PMID: 39159648
Background: A standardised dose-reduction strategy has not been established for the widely used gemcitabine plus nab-paclitaxel regimen in patients with metastatic pancreatic ductal adenocarcinoma. We aimed to investigate the efficacy...
8.
Karthaus M, Heinemann V, Riera-Knorrenschild J, Kretzschmar A, Welslau M, Kaiser U, et al.
BMC Cancer
. 2024 Jul;
24(1):887.
PMID: 39044160
Background: In the pivotal phase III RECOURSE trial, trifluridine/tipiracil (FTD/TPI) improved progression-free and overall survival (PFS, OS) of patients with pre-treated metastatic colorectal cancer (mCRC). Subsequently, the TALLISUR trial provided...
9.
Seufferlein T, Lausser L, Stein A, Arnold D, Prager G, Kasper-Virchow S, et al.
PLoS One
. 2024 Jun;
19(6):e0304324.
PMID: 38875244
Background: Anti-vascular endothelial growth factor (VEGF) monoclonal antibodies (mAbs) are widely used for tumor treatment, including metastatic colorectal cancer (mCRC). So far, there are no biomarkers that reliably predict resistance...
10.
Ettrich T, Modest D, Sinn M, Striefler J, Opitz B, Goetze T, et al.
J Clin Oncol
. 2024 Jun;
42(26):3094-3104.
PMID: 38843469
Purpose: First-line therapy options in advanced cholangiocarcinoma (CCA) are based on the ABC-02 trial regimen (gemcitabine/cisplatin [G/C]). The NIFE trial examined nanoliposomal irinotecan/fluorouracil/leucovorin (nal-IRI/FU/LV) as alternative first-line therapy in advanced...